Neutrophil-to-lymphocyte ratio (NLR) as a prognostic indicator of treatment response to novel hormones in metastatic castrate-resistant prostate cancer: Real-world data from a single institution.

被引：0
|
作者：
Scott, Emily [1 ]
Pasciuti, Katia [1 ]
Kubiak, Magdalena [1 ]
Marks, Gillian [1 ]
Needleman, Sarah [1 ]
Smith, Kate [1 ]
Prentice, Mark [1 ]
机构：
[1] Royal Free Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.52
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
52
引用
收藏
页数：2
相关论文
共 29 条
  • [1] Early Real-world Safety Data of Darolutamide in Non-metastatic Castrate-resistant Prostate Cancer
    Elumalai, T.
    Syndikus, I.
    Sundar, S.
    Choudhury, A.
    Conroy, R.
    Birtle, A.
    CLINICAL ONCOLOGY, 2022, 34 (03) : E144 - E145
  • [2] Radium-223 in the treatment of metastatic castrate-resistant prostate cancer: A real-world Irish experience
    Peters, Niamh
    Gaffney, John
    Connolly, Emma
    Bambury, Richard
    Power, Derek Gerard
    Kelly, Paul J.
    Jamaluddin, Muhammad Faisal
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [3] Real-World Cabazitaxel Use and Outcomes in Metastatic Castrate-Resistant Prostate Cancer: The Impact of Response to First ARPI
    Watson, Alexander S.
    Gagnon, Richard
    Batuyong, Eugene
    Alimohamed, Nimira
    Lee-Ying, Richard
    CLINICAL GENITOURINARY CANCER, 2022, 20 (05) : 496.e1 - 496.e9
  • [4] Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience
    Raju, Rachel
    Sahu, Arvind
    Klevansky, Myron
    Torres, Javier
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [5] Radium 223 treatment in metastatic castrate-resistant prostate cancer: Impact of sequencing on survival -Real-world outcomes from a single United Kingdom center.
    Jiang, Xue Yan
    Atkinson, Sarah
    Cuming, Sam
    Burns, Alexander
    Pearson, Rachel Anne
    Frew, John A.
    Azzabi, Ashraf S.
    McMenemin, Rhona Margaret
    Pedley, Ian David
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] A real-world retrospective analysis of the management of metastatic castrate-resistant prostate cancer in Ontario, Canada from 2010-2018
    Moldaver, Daniel M.
    Hassan, Shazia
    Seung, Soo Jin
    Edwin, Jonathan
    Clouthier, Derek L.
    Vera-Badillo, Francisco E.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (03) : 146.e13 - 146.e22
  • [7] Genomic/genetic testing patterns for patients with metastatic castrate-resistant prostate cancer: Results from a real-world study in the United States.
    Leith, Andrea
    Ribbands, Amanda
    Last, Matthew
    Gayle, Alicia
    Payne, Sarah
    McCrea, Charles
    Yang, Lingfeng
    Burgents, Joseph E.
    Ghate, Sameer
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [8] Role of neutrophil-to-lymphocyte, platelet-to-lymphocyte and myelocite-to-lymphocyte ratio as prognostic markers for immunotherapy response in patients with advanced solid tumors, a retrospective analysis from a single institution.
    Verrico, Monica
    Roberto, Michela
    Barchiesi, Giacomo
    Di Lisa, Francesca Sofia
    Arcuri, Teresa
    Vivona, Luca
    Fuccillo, Fernando
    Astorino, Vincenzo
    Buccilli, Dorelsa
    Maltese, Giulia
    Di Civita, Mattia Alberto
    Votto, Amedeo
    Ballario, Andrea
    Cara, Nertila
    de Meo, Simone
    Bianco, Vincenzo
    Speranza, Iolanda
    Botticelli, Andrea
    Tomao, Silverio
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] PROGNOSTIC VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) RECEIVING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED RADIONUCLIDE THERAPY
    Stangl-Kremser, Judith
    Sun, Michael
    Ho, Benedict
    Thomas, Joseph
    Nauseef, Jones
    Osborne, Joseph
    Molina, Ana
    Sternberg, Cora
    Nanus, David
    Bander, Neil
    Tagawa, Scott
    JOURNAL OF UROLOGY, 2023, 209 : E384 - E385
  • [10] Real-world treatment patterns with lutetium-177-PSMA-617 (177-Lu-PSMA) in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Dwabe, Sami
    Yazdanpanah, Omid
    Warnecke, Brian
    Benjamin, David Joseph
    Rezazadeh, Arash
    Mar, Nataliya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
123